Dissociative drugs

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, NMDA receptor antagonists, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Nutraceutical, Psychedelic drug

The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Key Points: 
  • The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.
  • Todays announcements are further evidence of the synergies between our growing clinic network and our contract research offerings, said Ketamine Ones Interim CEO, Adam Deffett.
  • We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One, added Mr. Deffett.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Sedatives, Ketamine, Neurocognition, IRPS

IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.

Key Points: 
  • IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.
  • NeuroCatch is expected to remain a key part of IRPs service offering as Ketamine One expands its network to new veteran-centric markets across Canada.
  • Unique service offerings such as NeuroCatch help Ketamine Ones clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time.
  • Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy.

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Patent

The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.

Key Points: 
  • The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.
  • I am pleased with our continued dedication to becoming a leader of novel ketamine products and implementing a patent strategy that would protect our clinical development and commercialization initiatives.
  • The patent application, entitled Methods and Compositions of Ketamine Formulation for Intradermal Administration, describes the potential improvement and therapeutic value of ketamine by delivering it through the skin.
  • PharmaTher is positioning itself as an innovator of novel uses, formulations and delivery forms of ketamine.

Leading Psychedelic Wellness Company Delic Completes Acquisition of Ketamine Infusion Centers LLC, Adding Health Clinic Chain to Portfolio

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, OTC Markets Group, WellPet, Delić

VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").
  • KIC will be strategically positioned to leverage DELIC platform and brand: DELIC expects to drive patients to KIC through its media platform and become a national leader
    Established history of providing ketamine infusion services.
  • "The DELIC team is committed to making psychedelic wellness accessible to the masses and with this chain of clinics we are making that vision possible."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Hallucinations, Stimulants, Hallucinogen, Dissociative, Dissociative drugs, Euphoriants, Lysergic acid diethylamide, Psychedelic drug, Phencyclidine, Empathogen–entactogen

Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Key Points: 
  • Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • A r eport from Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028.

Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc, Bringing Physical Retail Chain to Delic Portfolio

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, Sedatives, Chloroarenes, Nicotinic antagonists, Ketamine, WellPet, OTC Markets Group

VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, June 8, 2021 /PRNewswire/ -Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has signed a definitive agreement (the "Agreement") to acquire Ketamine Infusion Centers LLC ("KIC").
  • Supported by clinical trials and peer reviewed studies, ketamine infusions have emerged as a promising treatment option for chronic diseases and pain disorders.
  • We are focused on making psychedelic wellness truly accessible, and this is a huge development in the realization of that vision."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, General Health, Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketones, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Ketamine

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

Myconic Capital Becomes Ketamine One

Retrieved on: 
Tuesday, June 1, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Retrieved on: 
Wednesday, May 26, 2021
Psychoactive drugs, Drugs, Health, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Esketamine, Clinic, Ketamine, Mental health

Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.

Key Points: 
  • Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.
  • To view an enhanced version of this image, please visit:
    "The formation of our Medical Clinic Advisory Board is a critical next step in the creation of our clinics and treatment models.
  • Currently, ketamine and esketamine may legally be prescribed and administered in Canadian medical clinics, however there is a need for these clinics and treatments to be tailored to community and local health needs.
  • NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Retrieved on: 
Thursday, April 29, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, United States patent law, Pain management, Patent

b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.

Key Points: 
  • b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
  • 10,973,780, describing pharmaceutical formulations and treatment methods including the company\'s BB106 ketamine therapy.
  • This patent represents Bexson\'s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions.
  • The patent process is a long road and we are pleased to see this first one be issued," said Gregg Peterson, Bexson co-founder and CEO.\nThe company is engaging FDA to prepare for clinical trials evaluating its patented ketamine formula delivered subcutaneously.